Summary & Overview
Tendonitis, Myositis and Bursitis without MCC: Inpatient Reimbursement Overview
DRG 558 encompasses inpatient stays for tendonitis, myositis and bursitis without Major Complication or Comorbidity, focusing on inflammatory soft-tissue conditions that do not carry high-severity comorbidities. It matters for inpatient reimbursement because it defines the bundled payment level Medicare provides for these lower-severity musculoskeletal admissions.
DRG 558 Overview
DRG 558 covers inpatient admissions for tendonitis, myositis and bursitis without Major Complication or Comorbidity. These are soft-tissue inflammatory conditions affecting tendons, muscles and bursae that may require hospital-level pain control, immobilization or procedure-based interventions. This Diagnosis-Related Group matters for Medicare payment because it groups cases by expected resource use and sets the base inpatient reimbursement for hospitals when no higher-severity comorbidities are present. Understanding the clinical scope helps clarify payment relative to more complex musculoskeletal admissions.
Clinical Trials
- Acute procedural intervention trials investigating effectiveness and safety of minimally invasive tendon or bursa interventions (such as ultrasound-guided corticosteroid injections versus image-guided needle tenotomy) in hospitalized patients with severe tendonitis, myositis, or bursitis who have failed outpatient care; these studies enroll patients early in their inpatient course to measure short-term pain reduction, functional improvement, and avoidance of surgical escalation, and are relevant to providers and payers because demonstrated inpatient procedures that reduce length of stay or prevent higher-cost interventions can inform care pathways and resource allocation.
- Comparative effectiveness trials of multimodal nonoperative management strategies for moderate-to-severe inflammatory soft-tissue disorders in medically complex inpatients, comparing combinations such as optimized physical therapy regimens, systemic anti-inflammatory strategies, and localized therapies; these studies focus on patients with comorbidities (eg, diabetes, obesity, anticoagulation) who may respond differently to conservative care and address which bundles of therapies improve function and reduce readmissions, providing evidence to guide inpatient protocols and reimbursement decisions.
- Post-discharge outcomes and utilization studies examining long-term functional recovery, recurrence rates, outpatient rehabilitation needs, and healthcare utilization among patients discharged after inpatient treatment for tendonitis, myositis, or bursitis; these observational studies follow diverse populations (including older adults and those with work-related musculoskeletal issues) to identify predictors of readmission, durable functional outcomes, and cost drivers, which helps payers evaluate post-acute care benefits and providers design transitions of care that reduce downstream costs.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.